Barron's Streetwise

BofA analyst Geoff Meacham talks about downgrading Pfizer, upgrading Merck, and what he thinks will become the best selling medicine of all time. Learn more about your ad choices. Visit megaphone.fm/...

Home prices rose more than 40 percent between 2020 and 2022. What’s in store for next year? We revisit an episode from June on realtor and homebuilder stocks. Learn more about your ad choices. Visit ...

We revisit Jack's conversation with former Google CEO, Eric Schmidt. Jackson writes a podcast script with the help of deep learning. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Barron’s associate editor beat the market by 10 percentage points last year. He's back with a fresh list of names. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jack speaks with fixed income and stock strategists, and falls for a video head-fake from Shaq. Learn more about your ad choices. Visit megaphone.fm/adchoices

BofA Securities and Research Affiliates make the case. Plus, stock picks. Learn more about your ad choices. Visit megaphone.fm/adchoices

Chapek is out. Iger is back. What does it mean for the stock? Learn more about your ad choices. Visit megaphone.fm/adchoices

The Hasbro role-playing game has been an epic moneymaker. Why card values are crashing. Learn more about your ad choices. Visit megaphone.fm/adchoices

FTX becomes the latest crypto exchange to bite to dust. Plus, job cuts in tech bleed into other sectors? Learn more about your ad choices. Visit megaphone.fm/adchoices

Scott Galloway and an ARKK Invest Futurist weigh in on America’s new favorite wedge issue: Elon Musk. Learn more about your ad choices. Visit megaphone.fm/adchoices